This study provides the first evidence that SF-NVs can effectively treat MASH by orchestrating the HO-1-mediated anti-inflammatory response and restoring small intestinal homeostasis. Our findings define a novel paradigm for leveraging marine-derived nanotechnology to address metabolic crises, bridging the gap between sustainable marine resource utilization and next-generation oral therapeutics for inflammatory diseases.
Li et al. (Tue,) studied this question.